Back to Journals » Clinical Interventions in Aging » Volume 14

Current and emerging biomarkers of frailty in the elderly

Authors Al Saedi A, Feehan J, Phu S, Duque G

Received 16 November 2018

Accepted for publication 18 January 2019

Published 19 February 2019 Volume 2019:14 Pages 389—398

DOI https://doi.org/10.2147/CIA.S168687

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Dr Richard Walker


Ahmed Al Saedi,1,2 Jack Feehan,1,2 Steven Phu,1,2 Gustavo Duque1,2

1Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, Melbourne, VIC, Australia; 2Department of Medicine, Western Health, Melbourne Medical School, University of Melbourne, St Albans, Melbourne, VIC, Australia

Abstract: The term “frailty” is used to describe a subset of older adults who appear weaker and more vulnerable than their age-matched counterparts, despite having similar comorbidities, demography, sex, and age. The diagnosis of frailty is usually clinical and based on specific criteria, which are sometimes inconsistent. Therefore, there is an increasing need to identify and validate robust biomarkers for this condition. In this review, we summarize current evidence on the validity and practicality of the most commonly used biomarkers for frailty, while also comparing them with new upcoming strategies to identify this condition.

Keywords: frailty, biomarkers, COP cells, mesenchymal stem cells, disability, elderly

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]